Retargeted oncolytic viruses provoke tumor-directed T-cell responses.

Intratumoral application of oncolytic viruses effectively induce tumor-directed immune responses. However, their systemic application is typically insufficient to stimulate the required extent of tumor tissue inflammation to elicit antitumor immunity. We recently discovered evidence that this barrier can be overcome by effective molecular retargeting of viral infection. [ABSTRACT FROM AUTHOR]